New method for treating neuropathic pain

May 4, 2007 - Bovitrum has tested a novel method to treat aches and pains in a phase II clinical trial. Treatment for neuropathy is a chronic pain caused by nerve damage.

Contrary to current treatments that affect the brain, Bovitrum drugs will exert peripheral effects and directly affect damaged nerves. This area is in great demand for drugs but has not been met. The market price is estimated to be approximately 18 billion SEK. The study is expected to include up to 300 patients and expected results during the first half of 2008.

The drug tested at the moment is a protein activator (adenosine receptor 2A) that, among other things, has a direct duty to alleviate inflammation in the damaged nerve zone, in then available treatments suggest that mainly drugs are used to act on the brain.

The efficacy of these drugs is limited and high risk due to side effects such as; dizziness, nausea and sleepiness. Because Bovitrum's drugs affect the peripheral damaged areas in the body, the risk is reduced for these side effects, the effects are related to the central nervous system.

Therefore, this experiment shows a novel treatment, which reduces the risks of side effects and reduces pain as well as anti-inflammatory effects.

Danh Phuong